IBDEI1ET ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24992,2)
 ;;=^269591
 ;;^UTILITY(U,$J,358.3,24993,0)
 ;;=401.0^^144^1553^32
 ;;^UTILITY(U,$J,358.3,24993,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24993,1,2,0)
 ;;=2^401.0
 ;;^UTILITY(U,$J,358.3,24993,1,5,0)
 ;;=5^HYPERTENSION,MALIGNANT
 ;;^UTILITY(U,$J,358.3,24993,2)
 ;;=^73505
 ;;^UTILITY(U,$J,358.3,24994,0)
 ;;=242.90^^144^1553^33
 ;;^UTILITY(U,$J,358.3,24994,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24994,1,2,0)
 ;;=2^242.90
 ;;^UTILITY(U,$J,358.3,24994,1,5,0)
 ;;=5^HYPERTHYROIDISM
 ;;^UTILITY(U,$J,358.3,24994,2)
 ;;=^267811
 ;;^UTILITY(U,$J,358.3,24995,0)
 ;;=272.1^^144^1553^34
 ;;^UTILITY(U,$J,358.3,24995,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24995,1,2,0)
 ;;=2^272.1
 ;;^UTILITY(U,$J,358.3,24995,1,5,0)
 ;;=5^HYPERTRIGLYCERIDEMIA
 ;;^UTILITY(U,$J,358.3,24995,2)
 ;;=^101303
 ;;^UTILITY(U,$J,358.3,24996,0)
 ;;=251.2^^144^1553^35
 ;;^UTILITY(U,$J,358.3,24996,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24996,1,2,0)
 ;;=2^251.2
 ;;^UTILITY(U,$J,358.3,24996,1,5,0)
 ;;=5^HYPOGLYCEMIA NOS
 ;;^UTILITY(U,$J,358.3,24996,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,24997,0)
 ;;=276.1^^144^1553^36
 ;;^UTILITY(U,$J,358.3,24997,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24997,1,2,0)
 ;;=2^276.1
 ;;^UTILITY(U,$J,358.3,24997,1,5,0)
 ;;=5^HYPONATREMIA
 ;;^UTILITY(U,$J,358.3,24997,2)
 ;;=^60722
 ;;^UTILITY(U,$J,358.3,24998,0)
 ;;=276.8^^144^1553^37
 ;;^UTILITY(U,$J,358.3,24998,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24998,1,2,0)
 ;;=2^276.8
 ;;^UTILITY(U,$J,358.3,24998,1,5,0)
 ;;=5^HYPOPOTASSEMIA
 ;;^UTILITY(U,$J,358.3,24998,2)
 ;;=^60611
 ;;^UTILITY(U,$J,358.3,24999,0)
 ;;=458.9^^144^1553^38
 ;;^UTILITY(U,$J,358.3,24999,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24999,1,2,0)
 ;;=2^458.9
 ;;^UTILITY(U,$J,358.3,24999,1,5,0)
 ;;=5^HYPOTENSION NOS
 ;;^UTILITY(U,$J,358.3,24999,2)
 ;;=^60729
 ;;^UTILITY(U,$J,358.3,25000,0)
 ;;=244.9^^144^1553^39
 ;;^UTILITY(U,$J,358.3,25000,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25000,1,2,0)
 ;;=2^244.9
 ;;^UTILITY(U,$J,358.3,25000,1,5,0)
 ;;=5^HYPOTHYROIDISM NOS
 ;;^UTILITY(U,$J,358.3,25000,2)
 ;;=^123752
 ;;^UTILITY(U,$J,358.3,25001,0)
 ;;=599.71^^144^1553^5
 ;;^UTILITY(U,$J,358.3,25001,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25001,1,2,0)
 ;;=2^599.71
 ;;^UTILITY(U,$J,358.3,25001,1,5,0)
 ;;=5^HEMATURIA,GROSS
 ;;^UTILITY(U,$J,358.3,25001,2)
 ;;=^336611
 ;;^UTILITY(U,$J,358.3,25002,0)
 ;;=599.72^^144^1553^6
 ;;^UTILITY(U,$J,358.3,25002,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25002,1,2,0)
 ;;=2^599.72
 ;;^UTILITY(U,$J,358.3,25002,1,5,0)
 ;;=5^HEMATURIA,MICROSCOPIC
 ;;^UTILITY(U,$J,358.3,25002,2)
 ;;=^336612
 ;;^UTILITY(U,$J,358.3,25003,0)
 ;;=380.4^^144^1554^1
 ;;^UTILITY(U,$J,358.3,25003,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25003,1,2,0)
 ;;=2^380.4
 ;;^UTILITY(U,$J,358.3,25003,1,5,0)
 ;;=5^IMPACTED CERUMEN
 ;;^UTILITY(U,$J,358.3,25003,2)
 ;;=^62061
 ;;^UTILITY(U,$J,358.3,25004,0)
 ;;=607.84^^144^1554^2
 ;;^UTILITY(U,$J,358.3,25004,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25004,1,2,0)
 ;;=2^607.84
 ;;^UTILITY(U,$J,358.3,25004,1,5,0)
 ;;=5^IMPOTENCE
 ;;^UTILITY(U,$J,358.3,25004,2)
 ;;=^270441
 ;;^UTILITY(U,$J,358.3,25005,0)
 ;;=998.59^^144^1554^3
 ;;^UTILITY(U,$J,358.3,25005,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25005,1,2,0)
 ;;=2^998.59
 ;;^UTILITY(U,$J,358.3,25005,1,5,0)
 ;;=5^INFECTION,POST-OP
 ;;^UTILITY(U,$J,358.3,25005,2)
 ;;=^97081
 ;;^UTILITY(U,$J,358.3,25006,0)
 ;;=134.9^^144^1554^4
 ;;^UTILITY(U,$J,358.3,25006,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25006,1,2,0)
 ;;=2^134.9
 ;;^UTILITY(U,$J,358.3,25006,1,5,0)
 ;;=5^INFECTION,SKIN
 ;;
 ;;$END ROU IBDEI1ET
